Abstract
Detectable CMV-specific T cells in CMV-seronegative kidney transplant recipients (KTRs) have been attributed to an absence of circulating antibodies despite CMV-sensitization. The diagnostic value of CMV-specific T cells, however, needs to be implemented in risk stratification for CMV-replication. 326 KTRs were studied and classified with respect to CMV-serostatus and presence of CMV-specific T cells. Samples were collected pretransplantation, at +1, +2, and +3 months posttransplantation. CMV-specific T cells directed to CMV-IE1 and CMV-pp65 were measured by interferon-γ Elispot assay. 19/67 D+R- KTRs (28%) showed pretransplant CMV-specific T cells. Although no differences were observed for CMV-replication, KTRs with CMV-specific T cells presented with lower initial and peak CMV-loads (p<0.05). KTRs with decreasing/undetectable CMV-IE1-specific T cells pre and posttransplantation were at greatest risk of CMV-replication. KTRs with stable/increasing CMV-IE1-specific T cells from pre to posttransplantation, however, showed low risk of CMV-replication (p<0.001). 162/203 R+ KTRs (80%) showed pretransplant CMV-specific T cells. Decreasing/undetectable CMV-IE1-specific T cells from pre and posttransplantation identified those R+ KTRs at increased risk of CMV-replication (65/80 KTRs; 81%; p<0.001). Despite CMV-prophylaxis, D+R- KTRs are at greatest risk of CMV-disease. Our data suggest that monitoring CMV-specific T cell kinetics from pre to posttransplantation, particularly directed to CMV-IE1, offers superior risk stratification compared to CMV-serostatus alone.

This publication has 32 references indexed in Scilit: